Finance
Antidepressant Drugmaker Seaport Seeks $212.4 Million in US IPO
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, is seeking to raise $212.4 million in a US initial public offering.
B
Bloomberg
April 27, 2026·1 min read
Image: Bloomberg
Seaport Therapeutics Inc., a clinical-stage biotechnology company focused on antidepressants and anxiety drugs, is seeking to raise $212.4 million in a US initial public offering.
Original article
Antidepressant Drugmaker Seaport Seeks $212.4 Million in US IPO
Published by Bloomberg